Family · Pharmaceutical analytical standards
Dasatinib
A tyrosine kinase inhibitor that blocks the BCR-ABL protein and SRC family kinases: approved in the United States in June 2006 and in Europe in November of the same year, for chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?Its name honours Jagabandhu Das, one of the researchers on the project: when development had stalled, he was the one who questioned the chemists' starting assumptions.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
